GLSI
$28.16+0.03 (+0.09%)
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunother...
Recent News
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases
Key Insights Insiders appear to have a vested interest in Greenwich LifeSciences' growth, as seen by their sizeable...
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index up 0.2% and t
Top Midday Gainers
60 Degrees Pharmaceuticals (SXTP) reported Thursday a partnership with Runway Health to boost access
Wall Street Set to Open Higher Thursday as Investors Parse GDP, Unemployment Data, Look Ahead to Inflation Report
US stocks look set to open higher in Thursday's trading session as investors parse gross domestic pr
Investors Await Raft of Key Economic Data as US Futures Rise Thursday Pre-Bell
US stock futures are tracking higher in Thursday's premarket session as investors look ahead to a sl